2
Asgard Therapeutics has appointed Shane Olwill as Chief Development Officer
Asgard Therapeutics, a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy, has announced the appointment of experienced immunology drug development specialist Shane Olwill as Chief Development Officer (CDO).
Shane, who joins Asgard from Pieris Pharmaceuticals, now merged with NASDAQ-listed Palvella Therapeutics, will lead IND-enabling studies and clinical trials planning for Asgard’s lead asset AT-108.
During his thirteen years at Pieris, Shane played a…